SCHEDULE: ESSA Pharma: BVF Waives Ownership Limit, Exercises Warrants

ESSA Pharma Inc. and major shareholder BVF have agreed to waive a beneficial ownership limitation, allowing BVF to fully exercise its common share purchase warrants.

Summary

• ESSA Pharma Inc. and BVF (Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.) entered into a Waiver and Agreement to Exercise on August 5, 2025.
• The agreement waives Section 2(e) of the Warrants, which previously limited BVF's beneficial ownership to 19.99%, to permit the full exercise of their amended and restated common share purchase warrants (Pre-Funded Warrants).
• BVF, BVF2, and Trading Fund OS exercised all their Pre-Funded Warrants in a cashless exercise, acquiring 1,481,555, 1,234,964, and 203,325 shares, respectively, effective August 5, 2025.
• The total number of shares acquired through this exercise is 2,919,844.
• As of August 5, 2025, BVF beneficially owns 6,194,145 shares (13.1%), BVF2 owns 4,726,743 shares (9.99%), and Trading Fund OS owns 560,797 shares (1.2%).
• Collectively, entities associated with Mark Lampert (BVF Partners L.P./IL, BVF Inc./IL, Mark N. Lampert) beneficially own 11,668,473 shares, representing 24.7% of the outstanding shares.
• The total outstanding shares expected as of August 5, 2025, including the newly acquired shares, is 47,308,394 (44,388,550 pre-exercise + 2,919,844 exercised shares).

Sentiment

Score: 7

Explanation: The full exercise of warrants by a major investor, especially in anticipation of a merger, generally signals confidence and commitment, which is positive. However, the increased concentration of ownership and the resulting share dilution (from the exercise) could be viewed with some caution by other shareholders.

Positives

• A major institutional investor (BVF) is increasing its stake, indicating continued confidence in the company's prospects.
• The full exercise of warrants strengthens the investor's commitment and potentially simplifies the capital structure by converting warrants to common shares.
• The cashless exercise mechanism avoids immediate cash outflow for the investor while increasing the number of outstanding shares.

Negatives

• The significant increase in shares held by BVF (to 24.7% collectively) could raise concerns about shareholder concentration and potential influence on corporate decisions.
• The increase in outstanding shares (from 44,388,550 to 47,308,394) could lead to dilution for existing shareholders, although this is a result of warrant exercise, not a new issuance.

Risks

• The increase in a single entity's beneficial ownership (BVF group now holding 24.7%) could be perceived as a concentration risk for other shareholders, potentially impacting corporate control and decision-making.

Future Outlook

The warrant exercise by BVF is stated to be in connection with ESSA Pharma Inc.'s "proposed upcoming merger."

Management Comments

• The Company and BVF agreed to waive section 2(e) of the Warrants in respect of the Beneficial Ownership Limitation to permit the full exercise of the Warrants by BVF.
• BVF agreed that it will fully exercise all, but not less than all, of the Warrants effective as of the date hereof by delivering to the Company a duly completed and executed notice of exercise.

Industry Context

This transaction reflects a strategic move by a significant institutional investor in the biotechnology sector to consolidate its position ahead of a potential corporate event (merger). Such moves are common in the biotech industry, where strategic investments and M&A activity can significantly impact company valuations.

Comparison to Industry Standards

• Large institutional investors like BVF frequently take significant equity stakes in biotechnology companies, and the waiver of beneficial ownership limits to facilitate full warrant exercise is a strategic maneuver often employed to increase influence or prepare for M&A activities.
• The specific details of this transaction are unique to ESSA Pharma and BVF, and no direct comparable companies or projects are mentioned within the filing to benchmark against industry standards.

Corporate Governance

Related Party Transactions

• The Waiver and Agreement to Exercise between ESSA Pharma Inc. and BVF (a significant shareholder group) constitutes a related party transaction, allowing BVF to increase its beneficial ownership beyond a contractual limit.

Stakeholder Impact

• Shareholders: Potential dilution due to the increase in outstanding shares from warrant exercise; increased concentration of ownership by a major investor (BVF), which could impact future corporate control and strategic decisions.
• BVF (Investor): Increased equity stake and potential influence in ESSA Pharma Inc., especially ahead of a proposed merger.

Next Steps

• The Issuer's "proposed upcoming merger" is a key future event that this warrant exercise is connected to.

Key Dates

Recommendation

While the increased stake by a major investor like BVF signals confidence and commitment, the immediate impact of the cashless exercise is dilution for existing shareholders. The mention of a "proposed upcoming merger" introduces significant uncertainty and potential for both upside and downside. Given these factors, a "hold" recommendation is prudent until more details about the merger are available and its implications for the company's valuation and future strategy become clearer. The increased concentration of ownership also warrants observation.

Keywords

ESSA Pharma, BVF, Warrants, Share Exercise, Beneficial Ownership, SEC Filing, Schedule 13D, Biotechnology, Investment, Shareholder, Corporate Governance, Dilution